1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-12 am EDT
97.60 CHF   +0.62%
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
07/29Medacta Expects to Hit Top End of FY Revenue Guidance After 19% Growth in H1
MT
07/29MEDACTA : 2022 Half-Year Unaudited Top-Line Figures Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta Group SA Opens New Offices in Rancate, Switzerland

05/18/2022 | 12:00pm EDT

Medacta Group SA opened the doors of its new offices in Rancate. With an expansion of 2,100 square meters supporting the creation of more than 150 new jobs, the new building complements and works in complete synergy with the Castel San Pietro headquarters: two hubs of cutting-edge technology which continue to innovate responsibly for the benefit of patients, medical professionals, healthcare systems and the local community. The project includes two major expansions at both locations in Ticino. In Castel San Pietro, the production area will be expanded by about 5,300 square meters, bringing the total area to 15,300 square meters, with an increase of more than 50% in total area. The current 12,000 square meters in Rancate will be further expanded with a new area of about 9,500 square meters, dedicated to both offices and production, with an increase of almost 80% in operational space. In total, Medacta plants in Ticino are foreseen to cover more than 36'800 square meters.


© S&P Capital IQ 2022
All news about MEDACTA GROUP SA
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
07/29Medacta Expects to Hit Top End of FY Revenue Guidance After 19% Growth in H1
MT
07/29MEDACTA : 2022 Half-Year Unaudited Top-Line Figures Presentation
PU
07/29Medacta Group SA reports 19.0% growth of half-year revenue
EQ
07/29Medacta Group SA Announces Unaudited Revenue Results for the First Half Ended June 30, ..
CI
07/29Medacta Group SA Provides Revenue Guidance for the Year 2022
CI
06/23Medacta Announces First Lumbar Fusion Procedure with NextAR Augmented Reality Surgical ..
EQ
05/24MEDACTA : Company Presentation
PU
05/19Medacta Group announces the results of today's Annual General Meeting
EQ
05/19Medacta Group SA Approves Distribution
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 427 M 438 M 438 M
Net income 2022 57,0 M 58,4 M 58,4 M
Net Debt 2022 115 M 118 M 118 M
P/E ratio 2022 33,5x
Yield 2022 0,63%
Capitalization 2 017 M 2 069 M 2 069 M
EV / Sales 2022 4,99x
EV / Sales 2023 4,36x
Nbr of Employees 1 341
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 100,92 €
Average target price 115,60 €
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-31.27%2 069
ABBOTT LABORATORIES-20.79%195 226
MEDTRONIC PLC-8.34%125 988
BECTON, DICKINSON AND COMPANY7.29%75 203
HOYA CORPORATION-14.17%39 624
SARTORIUS STEDIM BIOTECH-20.96%36 037